COST-EFFECTIVENESS OF EMPAGLIFLOZIN (JARDIANCE) IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN THE UK BASED ON EMPA-REG OUTCOME DATA

被引：10
|
作者：
Daacke, I [1 ]
Kandaswamy, P. [2 ]
Tebboth, A. [3 ]
Kansal, A. [4 ]
Reifsnider, O. [4 ]
机构：
[1] Boehringer Ingelheim GmbH & Co KG, Bracknell, Berks, England
[2] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[3] Boehringer Ingelheim UK, Bracknell, Berks, England
[4] Evidera, Bethesda, MD USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.1876
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB46
引用
收藏
页码：A673 / A673
页数：1
相关论文
共 50 条
  • [11] Empagliflozin. Results of the EMPA-REG OUTCOME trial. A breakthrough in treatment of type 2 diabetes?
    Strojek, Krzysztof
    Rokicka, Dominika
    Szymborska-Kajanek, Aleksandra
    Wrobel, Marta
    CLINICAL DIABETOLOGY, 2016, 5 (03): : 107 - 110
  • [12] Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial
    Reifsnider, Odette S.
    Kansal, Anuraag R.
    Wanner, Christoph
    Pfarr, Egon
    Koitka-Weber, Audrey
    Brand, Sarah B.
    Stargardter, Matthew
    Wang, Cheng
    Kuti, Effie
    Ustyugova, Anastasia
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2022, 79 (06) : 796 - 806
  • [13] Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME
    Verma, Subodh
    Mazer, C. David
    Al-Omran, Mohammed
    Inzucchi, Silvio E.
    Fitchett, David
    Hehnke, Uwe
    George, Jyothis T.
    Zinman, Bernard
    CIRCULATION, 2018, 137 (04) : 405 - 407
  • [14] Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM)
    Kohler, S.
    Kaspers, S.
    Salsali, A.
    Zeller, C.
    Woerle, H. -J.
    DIABETOLOGIA, 2016, 59 : S26 - S26
  • [15] Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials
    Kamstra, Rhiannon
    Durkin, Mike
    Cai, Jennifer
    Bookhart, Brahim
    Lafeuille, Marie-Helene
    Pilon, Dominic
    Tiggelaar, Sean
    Manceur, Ameur M.
    Lefebvre, Patrick
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (03) : 280 - 287
  • [16] Cost-effectiveness Analysis of Empagliflozin in Japan Based on Results From the Asian subpopulation in the EMPA-REG OUTCOME Trial
    Kaku, Kohei
    Haneda, Masakazu
    Sakamaki, Hiroyuki
    Yasui, Atsutaka
    Murata, Tatsunori
    Ustyugova, Anastasia
    Chin, Rina
    Hirase, Tetsuaki
    Shibahara, Tsunehisa
    Hayashi, Naoyuki
    Kansal, Anuraag
    Kaspers, Stefan
    Okamura, Tomoo
    CLINICAL THERAPEUTICS, 2019, 41 (10) : 2021 - 2040
  • [17] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN COMBINATION WITH INSULIN FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN SPAIN
    Sanchez-Covisa, J.
    Capel, M.
    Schmidt, R.
    Charokopou, M.
    Verheggen, B. G.
    VALUE IN HEALTH, 2014, 17 (07) : A350 - A350
  • [18] THE EFFECT OF TREATMENT INTENSIFICATION ASSUMPTIONS ON ESTIMATES OF COST-EFFECTIVENESS IN TYPE 2 DIABETES MELLITUS (T2DM)
    Willis, M.
    Johansen, P.
    Neslusan, C.
    VALUE IN HEALTH, 2015, 18 (03) : A62 - A62
  • [19] COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN JAPAN BASED ON RESULTS FROM THE SUBGROUP ANALYSIS OF ASIAN PATIENTS IN THE EMPA-REG OUTCOME TRIAL
    Kaku, K.
    Haneda, M.
    Sakamaki, H.
    Yasui, A.
    Murata, T.
    Ustyugova, A., V
    Chin, R.
    Hirase, T.
    Shibahara, T.
    Hayashi, N.
    Kansal, A.
    Kaspers, S.
    Okamura, T.
    VALUE IN HEALTH, 2018, 21 : S128 - S128
  • [20] THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS SULFONYLUREA (SU) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN GERMANY
    Erhardt, W.
    Bergenheim, K.
    Townsend, R.
    Puelles, Fernandez de Troconiz J.
    McEwan, P.
    VALUE IN HEALTH, 2010, 13 (07) : A291 - A292
12345